Phase I study of multiple dose intramuscularly administered recombinant gamma interferon.
- 1 July 1986
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 4 (7), 1101-1109
- https://doi.org/10.1200/jco.1986.4.7.1101
Abstract
We report the results of a phase I study of the tolerance and biologic activity of intramuscularly (IM)-administered recombinant interferon-gamma (rIFN-gamma). Forty-four patients with metastatic cancer were given rIFN-gamma at doses ranging from 0.01 to 2.5 mg/m2/d for 42 days. The most common side effects were fever, flulike symptoms, night sweats, and granulocytopenia. The maximum tolerated dose was 0.5 mg/m2/d. Administration of rIFN-gamma resulted in modulation of immune system functions, including induction of major histocompatibility complex-associated antigens on blood leukocytes, an increase in blood surface immunoglobulin-bearing B cell and natural killer (NK) cell number, and NK cell cytotoxicity. Serum lysozyme, determined as an estimate of tissue macrophage activity, also increased. Serum assays for anti-interferon antibodies were negative in all patients. Five of eight evaluable patients with lymphoproliferative disorders showed objective evidence of tumor regression consisting of partial responses (two patients), and minor responses (three patients). These data suggest that further phase II studies of IM-administered rIFN-gamma are indicated.This publication has 21 references indexed in Scilit:
- Human Leukocyte Interferon to Control Thrombocytosis in Chronic Myelogenous LeukemiaAnnals of Internal Medicine, 1983
- Gamma interferon (IFN gamma) and IFN alpha/beta suppress murine myeloid colony formation (CFU-C)N: magnitude of suppression is dependent upon level of colony-stimulating factor (CSF).The Journal of Immunology, 1982
- Recombinant Leukocyte A Interferon: Pharmacokinetics, Single-Dose Tolerance, and Biologic Effects in Cancer PatientsAnnals of Internal Medicine, 1982
- Expression of human immune interferon cDNA in E. coli and monkey cellsNature, 1982
- Convenient assay for interferonsJournal of Virology, 1981
- Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents.Proceedings of the National Academy of Sciences, 1980
- Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant LymphomaAnnals of Internal Medicine, 1980
- Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferonCellular Immunology, 1980
- On the varied biologic effects of interferonCellular Immunology, 1977
- CELLULAR RESISTANCE TO INFECTIONThe Journal of Experimental Medicine, 1962